Tirzepatide studies show who improved and by how much

Tirzepatide changed hunger, insulin, and stored fat

Tirzepatide copies two hormones released by your gut after you eat ^[1]. One is called GLP-1; both give cells orders about hunger and blood sugar.

A 2020 study in cells found the drug sent the second hormone's message more strongly than GLP-1's message ^[1]. Researchers think the mix may help insulin keep doing its job with repeat shots.

The studies point to five main jobs:

1. Insulin rises when blood sugar is high. GLP-1 and the second hormone prompt the pancreas to release insulin then, which helps avoid very low sugar ^[1][2].
2. The liver puts less sugar into the blood. GLP-1 lowers a hormone that tells the liver to send sugar out ^[2].
3. The stomach empties more slowly at first. This can blunt the sugar rise after meals, though the slowing fades ^[10].
4. People feel less hungry. Both hormones reach brain areas that tell you when you've eaten enough ^[22].
5. Fat cells may release stored fuel. The second hormone may help when you eat fewer calories ^[21].

These changes may explain why people lost more weight than with drugs that copy just one hormone ^[1][21][22]. No study has proved that the insulin, liver, stomach, hunger, or fat-cell change alone caused the extra loss.

Tirzepatide kept hunger lower after the stomach sped up

Tirzepatide copies both gut hormones together, including GLP-1 ^[1][22]. They release insulin, cut sugar from the liver, slow the stomach, and ease hunger.

The stomach slowed most after the first shot, then neared its old speed ^[10]. Yet help with hunger and insulin lasted while people kept taking tirzepatide.

In cell tests, tirzepatide sent the GLP-1 message in a different way from older drugs ^[1]. Researchers don't know whether that difference improved weight or blood sugar in people.

Tirzepatide cut average weight most at the highest amounts

Four large SURMOUNT studies tracked adults with excess weight. Each was a phase 3 test done near the end of drug testing.

SURMOUNT-1 tracked 2,539 people without diabetes for 72 weeks. The average loss was 16.0% at 5 mg, 21.4% at 10 mg, and 22.5% at 15 mg. People given placebo, which had no medicine, lost 2.4% ^[5].

At the two highest amounts, 96% lost at least 5%. That highest average was larger than prior drug studies had found.

SURMOUNT-3 started with a 12-week period of strict food and activity work. People first lost at least 5%. Tirzepatide brought 18.4% more loss over 72 weeks, while placebo brought a 2.5% gain ^[6].

From the first day, average loss reached 26.6%. No earlier study of this kind had found a larger average.

SURMOUNT-4 looked at stopping the drug. One group switched from tirzepatide to placebo. Average weight rose 14.0% during the next 52 weeks.

Of those who kept taking tirzepatide, 89.5% held at least 80% of their loss. Only 16.6% of the placebo group did ^[7].

SURMOUNT-1 found that large losses lasted through the study

Over 72 weeks, average loss reached 20.9% at 10 mg and 22.5% at 15 mg ^[5]. After the food and activity work, SURMOUNT-3 reached 26.6% ^[6].

Those averages neared results once seen mostly after weight-loss surgery. If time or cost concerns you, ask what ending care could mean.

Tirzepatide lowered the months-long blood sugar test

The 10 SURPASS studies followed adults with type 2 diabetes for 40–52 weeks. They were phase 3 studies done near the end of drug testing.

SURPASS-1 compared tirzepatide with placebo for 40 weeks. The test of average blood sugar fell 1.87% at 5 mg, 1.89% at 10 mg, and 2.07% at 15 mg ^[2].

In all, 81–86% reached 6.5% or less. At the highest amount, 31–52% reached the usual range below 5.7%.

SURPASS-2 compared two weekly drugs for 40 weeks. Tirzepatide cut weight and average blood sugar by more than semaglutide 1 mg, a weekly drug based on one gut hormone.

At 15 mg, the blood sugar test fell another 0.45 points. People lost 11.2 kg with tirzepatide and 5.3 kg with semaglutide ^[3].

SURPASS-4 tracked people likely to have heart trouble for 52 weeks. At 15 mg, average blood sugar fell 2.58%. People given insulin glargine, a long-lasting insulin shot, gained 1.9 kg ^[4].

The heart finding's 95% range included no benefit and fewer heart problems. Since both fit the facts, this study didn't prove fewer heart attacks, strokes, or heart deaths.

Weight also fell by a large amount

At 15 mg, average loss in the main studies was about 20–22% or more ^[5][8]. SURMOUNT-5 found tirzepatide led to more loss than the highest semaglutide amount ^[8].

Tirzepatide beat semaglutide on average weight loss

Three groups of findings directly compare the drugs. Semaglutide is another weekly drug, but it acts like GLP-1 alone.

SURPASS-2 followed people with diabetes for 40 weeks. It tested tirzepatide 15 mg beside semaglutide 1 mg.

Each of the three tirzepatide amounts cut weight and average blood sugar more ^[3]. At 15 mg, people lost 11.2 kg with tirzepatide and 5.3 kg with semaglutide.

SURMOUNT-5 tracked 751 adults with excess weight and no diabetes for 72 weeks. It was the first study built to compare these drugs for weight.

Tirzepatide up to 15 mg brought 20.2% average loss. Semaglutide up to 2.4 mg brought 13.7%. Loss of at least 30% occurred in 19.7% and 6.9%; waists shrank 18.4 cm and 13.0 cm ^[8].

At the highest amounts, stomach trouble was much alike. Nausea was slightly more common with tirzepatide ^[23].

Reviews that joined several studies reached the same result. Those reviews found weight and blood sugar fell farther with tirzepatide, most clearly at 15 mg versus 2.4 mg ^[3][8].

Neither group average can choose a drug for you. Ask how the gains, side effects, cost, and time would fit your health.

Tirzepatide helped people's bodies answer insulin

Blood tests showed that insulin worked better

As people lost weight, insulin did a better job moving sugar from blood into cells. SURPASS-2 gave the clearest finding among 1,879 people.

From 5–15 mg, insulin worked better with tirzepatide than with semaglutide 1 mg, a GLP-1 drug ^[11]. A blood test doesn't show how much better someone felt.

The stronger response appeared at every tirzepatide amount and was unlikely to be chance. Still, the group finding can't forecast your next test.

Insulin-making cells released more insulin when sugar rose

SURPASS-4 found that these pancreas cells answered rising blood sugar more strongly ^[4][11]. That is how the cells help keep sugar from staying high.

The SURPASS-2 result was larger with tirzepatide than with a drug acting like one gut hormone ^[11]. The finding may reflect better cell work, weight loss, or both.

SURPASS-2 didn't show how much help came from the second gut hormone. The study also can't tell whether the cells will keep working longer.

The studies didn't show that damaged cells healed

SURPASS-4 found that insulin-making cells worked better during the study. It didn't show that tirzepatide stops or reverses type 2 diabetes.

Tirzepatide slowed the stomach most after the first shot

One copied gut hormone slows food leaving your stomach. Researchers tracked acetaminophen, a common pain pill, to time that movement.

After the first shot, the pill's highest blood level fell 50%. The peak came later too ^[10], meaning the pill had stayed in the stomach longer.

After several weeks at one amount, the delay was much smaller. In mice, the second gut hormone alone didn't slow the stomach ^[10].

This can matter when a pill must work at a set time. Your prescriber can check each name on your medicine list.

Tirzepatide kept hunger low after stomach slowing faded

Brain areas that control hunger receive messages from GLP-1 and the second copied hormone ^[22]. In rats and mice, one hormone made the other's effect on hunger stronger.

Small studies found that people still ate less after their stomachs stopped emptying slowly ^[22]. The phase 3 studies haven't published brain scans.

People in the main weight study ate far less than stomach slowing could explain ^[5][22]. A brain effect is likely, but it hasn't been proved.

Tirzepatide lowered the top blood pressure number

The top number fell 4–13 millimeters of mercury, the unit on your cuff. Among people starting above 140 millimeters of mercury, it fell 14–17.5 millimeters of mercury.

A review joined 5 studies that began with SURPASS-1 and covered more than 13,000 people. It compared each person's weight and pressure, then found weight loss explained 33–57% of the pressure drop ^[12].

Pulse rose by 1–6 beats each minute. Similar gut-hormone drugs can do that, so ask which pulse change needs a call.

The second gut hormone may free stored fat

After a meal, the second gut hormone helps fat cells store fuel. When you eat less, the same hormone may help the cells release it ^[21].

Researchers saw the change in human fat cells grown in a lab and in mice ^[21]. Those lab and mouse results can't prove your body responds the same way.

Copying GLP-1 and the second hormone may add help

The second hormone may help use fat, ease nausea, and release insulin from the pancreas ^[1][21]. Drugs copying GLP-1 alone don't send the second hormone's message.

SURPASS-2 found that insulin worked better with tirzepatide than with semaglutide 1 mg, a GLP-1 drug ^[11]. The stronger response appeared at all three tirzepatide amounts, but researchers don't know why.

People regained much of the weight after stopping tirzepatide

In SURMOUNT-4, people switched from tirzepatide to placebo and gained back 14.0% over 52 weeks ^[7]. Within one year, they had regained two-thirds of the weight lost.

Of those who stayed on tirzepatide, 89.5% kept at least 80% of their loss. Just 16.6% of people on placebo did.

Similar drugs also leave people hungrier after they stop. None removes every lasting cause of weight gain, such as hunger, illness, sleep, and daily habits.

SURMOUNT-4 suggests that weight care may take years ^[7]. Ask what stopping could mean for your health, weight, time, and cost.